Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Grows By 8.6%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 31st total of 4,440,000 shares. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is presently 12.0 days. Currently, 19.6% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ARCT. BTIG Research began coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $61.60.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. Empire Life Investments Inc. raised its stake in shares of Arcturus Therapeutics by 85.5% during the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after acquiring an additional 128,771 shares in the last quarter. Spire Wealth Management boosted its stake in shares of Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 10,746 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 3,705 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after purchasing an additional 47,824 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Arcturus Therapeutics by 3.7% in the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 2,335 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Down 6.9 %

Shares of Arcturus Therapeutics stock opened at $15.80 on Tuesday. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The stock’s 50-day simple moving average is $17.27 and its 200-day simple moving average is $19.41. The company has a market capitalization of $428.02 million, a price-to-earnings ratio of -7.12 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the prior year, the company earned ($0.61) EPS. On average, equities analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.